Citi analyst Samantha Semenkow upgraded BioAge Labs (BIOA) to Buy from Neutral with a price target of $10, up from $5. The firm believes the company’s BGE-102, an oral NLRP3 inhibitor being developed for obesity, could be “differentiating.” BGE-102 is a “potentially differentiated” NLRP3 inhibitor that could be given in combination with oral GLP1s or be a monotherapy, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIOA: